Alterity Therapeutics Limited (ATHE): Price and Financial Metrics
ATHE Price/Volume Stats
| Current price | $2.16 | 52-week high | $5.41 |
| Prev. close | $2.13 | 52-week low | $1.55 |
| Day low | $2.14 | Volume | 2,203 |
| Day high | $2.16 | Avg. volume | 76,008 |
| 50-day MA | $1.94 | Dividend yield | N/A |
| 200-day MA | $2.38 | Market Cap | 10.09M |
ATHE Stock Price Chart Interactive Chart >
Alterity Therapeutics Limited (ATHE) Company Bio
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.
Latest ATHE News From Around the Web
Below are the latest news stories about ALTERITY THERAPEUTICS LTD that investors may wish to consider to help them evaluate ATHE as an investment opportunity.
Alterity Therapeutics Appoints Phillip Hains as Chief Financial OfficerMELBOURNE, Australia and SAN FRANCISCO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the appointment of Phillip Hains as the Company’s new Chief Financial Officer (CFO), effective 31 January 2024. Mr. Hains has served as the Company Secretary of Alterity since 2014, and his experience includes almost 30 yea |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time to dive into the biggest pre-market stock movers as we check out all of the hottest trading news for Tuesday morning! |
Alterity (ATHE) Up on Preclinical Parkinson's Treatment DataData from a preclinical study shows that treatment with Alterity's (ATHE) lead candidate improved motor performance and general function in monkeys with experimentally-induced Parkinson's disease. |
Why Is Alterity Therapeutics (ATHE) Stock Up 150% Today?Although Alterity Therapeutics revealed encouraging data with its PD therapeutic candidate, ATHE stock still faces challenges. |
Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical ProgressMELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be hosting an investor webcast on Wednesday, 6 December 2023 in Australia / Tuesday, 5 December 2023 in the United States. Details are listed below and registration is required. The call will be hosted by Alterity’s CEO Dr. David Stam |
ATHE Price Returns
| 1-mo | 26.32% |
| 3-mo | 7.48% |
| 6-mo | -12.90% |
| 1-year | -23.79% |
| 3-year | -86.42% |
| 5-year | -83.38% |
| YTD | -13.25% |
| 2023 | -28.49% |
| 2022 | -51.64% |
| 2021 | -46.27% |
| 2020 | 71.79% |
| 2019 | -39.06% |
Loading social stream, please wait...